SCHD Pays $8,384 More a Year Than SCHG. Over Five Years SCHG Returned $121,800 More
SCHD and SCHG split the same $300,000 in opposite directions depending on which measuring stick you pick, and the one most investors grab first may be the wrong one for their situation.
Cathie Wood Says the Memory Chip Trend Is Up but the Cycles Are ‘Vicious’
Cathie Wood is steering ARK away from memory chips just as Micron and SanDisk post some of the fastest margin expansions in their histories, and her reasoning about Chinese rivals may explain why those gains look fragile.
A 4.56% slide to $199.84 wipes roughly $14 billion off a $311.5 billion consumer-staples name that rarely moves like this. The $200 line is the level to keep an eye on from here.
You Retired on a Friday and Monday Nothing Hit the Bank. These 4 ETFs Are the Paycheck That Replaces the One That Stopped
Payroll stops the moment you retire, and nothing steps in automatically to fill that gap. Four ETFs can rebuild a monthly income stream, but when and how you collect from them determines whether your checking account survives the wait.
Operating income rose just 2% as purchased transportation, insurance and driver costs ate the gains from 20.4% year over year revenue growth, and the stock dropped on the filing. Intermodal loads up 8% keep the freight story intact, and investors are repricing the margins.
Record core net new assets of $190.4 billion, up 38% year over year, pushed total client assets to $13.33 trillion and carried earnings past consensus for a fifth straight quarter. Revenue came in narrowly missing expectations, and management now expects full-year revenue at the low end of prior guidance.
Free cash flow swung to $472 million as alumina output rose 11% sequentially on a steadier Pinjarra refinery, carrying earnings well past consensus even with revenue slightly missing expectations. Management flagged roughly $60 million of Q4 headwinds in the Aluminum segment from raw material costs and alumina pricing, with the South32 asset deal still set to close in the first half of 2027.
Iambic Therapeutics prices IPO at $16, raising $150 million
Priced at $16 a share, the AI drug discovery developer raised $150 million on 9.375 million shares, with J.P. Morgan, Jefferies, BofA and Citigroup running the books. Terms are final, so trading opens from here.
Source: SEC filingThe board just raised the quarterly dividend 71% to $0.15 a share, a confidence signal that lands the same day earnings missed consensus by a fraction of a cent and snapped five straight quarters of beats. Revenue still came in ahead of estimates.
A 7.4% intraday run to $4.85 adds roughly $330 million to this $4.8 billion eVTOL name in a single session. Moves this size still swing a stock trading under $5, so keep an eye on whether it holds the level.
A 7.2% run to $22.87 adds roughly $700 million to Figma's $10.4 billion market value in one session. For a design software name still finding its post-IPO footing, moves this size set the near-term trading range.
A 4.07% move is outsized for a ratings giant that rarely jumps, adding roughly $3 billion of market cap in one session. Worth watching whether it holds into tomorrow's open.


